• Corporate Web Site
• Français
• 

• Home
• Corporate Profile
• Technical Aspects of the 125L Ozone Sterilizer
• 2007 Annual Review
• Message from the Management
• Perspectives
• Analysis of Financial Situation and Operating Results
• Financial Statements
• Directors
• Scientific Advisory Board
• Investors' Information
• Acknowledgements

A strong and attractive future

The referral site program now ended, and the sales closed to date, put us in an ideal position for the group of innovative clients from nearly 30 healthcare institutions throughout North America.

A clear path, healthy foundation and flourishing future

The overall strategy of TSO₃ is in constant evolution. Today, it must take into account the challenge of flexible endoscopes and the expected potential of deactivating infectious prions. The new reality we face allows to anticipate modest growth in sales for 2008. Therefore, our objective in the short term is to focus our sales efforts on customers that have shown an immediate need for our product, while ensuring sales in the pipeline for 2009.

We continue to successfully take on the challenges in the current sterilization market, one after another. Our priority is also to make our product better known and recognized among hospital managers.

Our growing number of customers continue to testify to our efficacy and to the benefits of our product – a key element in our strategy. In parallel, our sales force is polishing its expertise on the ground and taking advantage of ever greater business opportunities, thanks to the numerous successes we obtain as a team, such as the agreement recently signed with Broadlane.

Our financial situation is healthy, our experience ever greater and our management cautious, allowing us to maintain the efforts necessary to our success.